siRNA and MHC Class I Therapy for ALS Motor Neuron Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for amyotrophic lateral sclerosis (ALS) lack effective mechanisms to address the toxic function of astrocytes, which contribute to motor neuron death, particularly due to the expression of cytoplasmic granule toxins like perforin and granzyme B, and insufficient MHC class I expression in motor neurons.
Innovation Solution
Developing pharmaceutical compositions and methods that decrease the expression of cytoplasmic granule toxins in astrocytes and increase MHC class I expression in motor neurons using nucleic acids, such as siRNA, shRNA, and antisense RNA molecules, delivered via bacterial or viral vectors, to protect motor neurons from toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for ALS, then treatment is provided, but they fail to address the toxic function of astrocytes and insufficient MHC class I expression in motor neurons
Solution Approach 1:
The therapy is divided into two distinct molecular mechanisms: (1) siRNA-mediated knockdown of perforin and granzyme B expression in astrocytes to reduce cytotoxicity, and (2) gene therapy delivery of MHC class I molecules to motor neurons to enhance protective expression. This segmentation allows each mechanism to be optimized independently for its specific therapeutic target.
Solution Approach 2:
Viral vectors serve as intermediaries to deliver both the siRNA molecules to astrocytes and the MHC class I gene constructs to motor neurons. These vectors mediate the transfer of therapeutic genetic material across the blood-brain barrier and into specific cell types, enabling the therapy to reach its targets effectively.
2Reliability
If cytoplasmic granule toxins are expressed in astrocytes, then astrocyte function is maintained, but motor neuron death is promoted
Solution Approach 1:
The therapy converts the harmful cytotoxic function of astrocytes into a beneficial outcome by using siRNA to selectively silence the expression of perforin and granzyme B genes in astrocytes. This reduces their ability to kill motor neurons while preserving other essential astrocyte functions through selective gene knockdown rather than complete astrocyte elimination.
3Object-affected harmful factors
If MHC class I expression is insufficient in motor neurons, then motor neuron vulnerability increases, but immune protection decreases
Solution Approach 1:
The therapy performs preliminary action by proactively increasing MHC class I expression in motor neurons before disease progression occurs or before cytotoxic attacks by astrocytes. This preventive approach establishes protective immune recognition mechanisms in advance, allowing motor neurons to be better prepared against potential immune-mediated damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces astrocyte-mediated toxicity to motor neurons, increasing their survival, preventing soma atrophy, and promoting neurite length, thereby offering potential therapeutic benefits for both sporadic and familial ALS.
Implementation Method 1
using nucleic acids, such as siRNA, shRNA, and antisense RNA molecules
Data Source
AI summary
The invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis. In particular, the invention relates to pharmaceutical compositions, kits, methods, and uses for the treatment of amyotrophic lateral sclerosis by decreasing the expression of a cytoplasmic granule toxin in astrocytes of a patient, or by increasing the expression of MHC class I in motor neurons of the patient.